KR950700063A - Brofaromine as an agent for treating post-traumatic stress - Google Patents

Brofaromine as an agent for treating post-traumatic stress

Info

Publication number
KR950700063A
KR950700063A KR1019940702903A KR19940702903A KR950700063A KR 950700063 A KR950700063 A KR 950700063A KR 1019940702903 A KR1019940702903 A KR 1019940702903A KR 19940702903 A KR19940702903 A KR 19940702903A KR 950700063 A KR950700063 A KR 950700063A
Authority
KR
South Korea
Prior art keywords
broparomin
pharmaceutically acceptable
effective amount
acceptable salt
warm
Prior art date
Application number
KR1019940702903A
Other languages
Korean (ko)
Inventor
리챠드 카쯔
Original Assignee
베르너 발데크
시바-가이기 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 베르너 발데크, 시바-가이기 아게 filed Critical 베르너 발데크
Publication of KR950700063A publication Critical patent/KR950700063A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

본 발명에서는 브로파로민 또는 제약학상 허용되는 이의 염의 외상후 스트레스성 장해치료 유효량을 그러한 치료를 필요로 하는 온형 동물에게 투여함을 포함하여 온혈 동물의 외상후 스트레스성 장해를 치료하는 방법이 제공된다.The present invention provides a method for treating posttraumatic stress disorder in warm-blooded animals, including administering an effective amount of a posttraumatic stress disorder disorder of broparomin or a pharmaceutically acceptable salt thereof to a warm-blooded animal in need thereof. .

Description

외상후 스트레스 치료제로서의 브로파로민(Brofaromine as an agent for treating post-traumatic stress)Brofaromine as an agent for treating post-traumatic stress

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is an open matter, no full text was included.

Claims (10)

브로파로민 또는 제약학상 허용되는 이의 염의 외상후 스트레스성 장해 치료 유효량을 그러한 치료를 필요로 하는 온혈 동물에게 투여함을 포함하여 온혈 동물의 외상후 스트레스성 장해를 치료하는 방법.A method of treating posttraumatic stress disorder in a warm blooded animal, comprising administering a therapeutically effective amount of a broparomin or a pharmaceutically acceptable salt thereof to a warm blooded animal in need thereof. 제1항에 있어서, 온혈 동물이 인간인 것인 방법.The method of claim 1, wherein the warm-blooded animal is a human. 제1항에 있어서, 상기 유효량이 유리 브로파로민을 기준으로 하여 약 0.1mg/kg 내지 약 5.0mg/kg인 것인 방법.The method of claim 1, wherein said effective amount is from about 0.1 mg / kg to about 5.0 mg / kg based on free broparomine. 제1항에 있어서, 상기 브로파로민의 제약학상 허용되는 염이 염산염인 것인 방법.The method of claim 1, wherein the pharmaceutically acceptable salt of broparomin is hydrochloride. 제1항에 있어서, 상기 투여 방법이 경구 또는 정맥내 경로를 통하는 것인 방법.The method of claim 1, wherein said method of administration is via an oral or intravenous route. 제1항에 있어서, 상기 브로파로민 또는 제약학상 허용되는 이의 염이 상기 브로파로민 또는 이의 염이외에 제약학상 허용되는 담체를 포함하는 조성물의 형태로 투여되는 것인 방법.The method of claim 1, wherein the broparomin or a pharmaceutically acceptable salt thereof is administered in the form of a composition comprising a pharmaceutically acceptable carrier other than the broparomin or a salt thereof. 제1항에 있어서, 상기 브로파로민 또는 이의 염을 정제 또는 캡슐제 형태로 경구 투여하는 것인 방법.The method of claim 1, wherein the broparomin or salt thereof is orally administered in the form of a tablet or capsule. 통상의 제약학적 보조제와 혼합된 브로파로민 또는 제약학상 허용되는 이의 염의 사회적 공포증 치료 유효량을 함유하는, 외상후 스트레스성 장해를 치료하기 위한 제약학적 조성물.A pharmaceutical composition for the treatment of posttraumatic stress disorder, which contains a therapeutically effective amount of broparomin or a pharmaceutically acceptable salt thereof in admixture with a conventional pharmaceutical adjuvant. 제8항에 있어서, 상기 유효량이 유리 브로파로민을 기준으로 약 0.1mg/kg 내지 약 5.0mg/kg인 것인 제약학적 조성물.The pharmaceutical composition of claim 8, wherein the effective amount is from about 0.1 mg / kg to about 5.0 mg / kg based on free broparomine. 제8항에 있어서, 염산염으로 브로파로민 25내지 100mg을 함유하는 정제 또는 캡슐제 또는 주사제 용액의 형태인 것인 제약학적 조성물.The pharmaceutical composition according to claim 8, which is in the form of a tablet or capsule or injection solution containing from 25 to 100 mg of broparomin as the hydrochloride. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019940702903A 1992-02-21 1993-01-27 Brofaromine as an agent for treating post-traumatic stress KR950700063A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83963992A 1992-02-21 1992-02-21
US07/839,639 1992-02-21
PCT/US1993/000728 WO1993016695A1 (en) 1992-02-21 1993-01-27 Brofaromine as an agent for treating post-traumatic stress

Publications (1)

Publication Number Publication Date
KR950700063A true KR950700063A (en) 1995-01-16

Family

ID=25280288

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019940702903A KR950700063A (en) 1992-02-21 1993-01-27 Brofaromine as an agent for treating post-traumatic stress

Country Status (7)

Country Link
EP (1) EP0626849A1 (en)
JP (1) JPH07503972A (en)
KR (1) KR950700063A (en)
AU (1) AU676672B2 (en)
CA (1) CA2117430A1 (en)
NZ (1) NZ249041A (en)
WO (1) WO1993016695A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1096927A4 (en) * 1998-07-16 2002-09-04 Massachusetts Inst Technology Composition for treatment of stress
US6579899B1 (en) 1998-07-16 2003-06-17 Massachusetts Institute Of Technology Composition for treatment of stress
WO2001027612A2 (en) * 1999-10-12 2001-04-19 Connex Gesellschaft Zur Optimierung Von Forschung Und Entwicklung Mbh Immuno-chromatographic rapid assay in order to detect acid-resistant microorganisms in the stool

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH592656A5 (en) * 1973-03-02 1977-10-31 Ciba Geigy Ag
AU3595093A (en) * 1992-02-21 1993-09-13 Ciba-Geigy Ag Brofaromine as an agent for treating social phobia

Also Published As

Publication number Publication date
EP0626849A1 (en) 1994-12-07
AU3484493A (en) 1993-09-13
AU676672B2 (en) 1997-03-20
WO1993016695A1 (en) 1993-09-02
CA2117430A1 (en) 1993-09-02
JPH07503972A (en) 1995-04-27
NZ249041A (en) 1997-07-27

Similar Documents

Publication Publication Date Title
RU2203653C2 (en) Using n-propargyl-1-aminoindane r-enantiomer, its salts and compositions comprising thereof
KR930702022A (en) Treatment or prevention of type 1 diabetes by oral administration of insulin
KR950031069A (en) How to suppress bone loss and lower serum cholesterol
KR880011199A (en) Novel peptide compounds, methods for their preparation and pharmaceutical compositions containing them
EA200000468A1 (en) THERAPEUTIC COMPOSITION FOR THE ADMINISTRATION OF TOLTERODINE WITH CONTROLLED DELIVERY
UA41446C2 (en) Use of fumagilol or its derivatives for preparing drugs intended for treating intestinal infection and pharmaceutical composition
KR890001533A (en) Pharmaceutical compositions containing levodopa methyl esters, their preparation and therapeutic applications
KR900701282A (en) Treatment, prevention of ischemic diseases of the heart or brain
DE59406938D1 (en) PHARMACEUTICAL PREPARATIONS WITH AN ACTIVE SUBSTANCE CONTAINING MODIFIED AMIDINE GROUPS
KR950007848A (en) Treatment of Anxiety with (S)-(-)-α-ethyl-2-oxo-1-pyrrolidineacetamide
KR830002510A (en) Composition consisting of biologically active compound and hydroxyalkyl starch
KR940702726A (en) Use of substituted quinoline-3-carboxyamide compounds and methods of treating multiple sclerosis using the same
KR920019350A (en) Pharmaceutical Compositions for Autoimmune Disease Therapy
RU97104483A (en) SUITABLE ACID SALT 4- [2-AMINO-6- (CYCLOPROPYLAMINO) -9H-PURIN-9-IL] -2- CYCLOPENTEN-1-METHANOL AS ANTI-VIRUS AGENT
ES2093246T3 (en) THERAPEUTIC BENZAZEPINE COMPOUNDS.
KR920702225A (en) Pharmaceutical composition
KR950700063A (en) Brofaromine as an agent for treating post-traumatic stress
KR890004705A (en) Antiviral agents
OA07029A (en) Gallium chloride, a new anti-cancer drug.
KR890012942A (en) 5-substituted ornithine derivatives
KR960700711A (en) Medicine for treating or preventing cerebrovascular diseases
KR900701278A (en) Bile acids for the treatment of viral infections
KR880004810A (en) Peptic Ulcer Treatment
KR930702985A (en) Treatment of Esophageal Cancer
KR830009776A (en) Induction of Cell Protection

Legal Events

Date Code Title Description
N231 Notification of change of applicant
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application